Understanding how kidney cancer cells evade the immune system
Genetic Mechanisms Controlling Kidney Cancer Immune Escape
This study is looking at how kidney cancer cells hide from the immune system, especially the important T-cells that help fight cancer, to find ways to make immunotherapy treatments work better for people with clear cell renal cell carcinoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11061349 on NIH RePORTER |
What this research studies
This research investigates the genetic mechanisms that allow kidney cancer cells to escape detection and destruction by the immune system, particularly focusing on CD8 T-cells, which are crucial for fighting cancer. The study aims to identify the specific genetic features that inhibit the formation of an immune-supportive niche within tumors, which is essential for the survival and effectiveness of anti-tumor T-cells. By analyzing cancer cells from patients with clear cell renal cell carcinoma (RCC), the researchers hope to uncover insights that could enhance the effectiveness of immunotherapies. The approach includes advanced techniques like RNA sequencing to understand the relationship between tumor genetics and immune response variability among patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who are undergoing treatment or have recently had surgery.
Not a fit: Patients with other types of kidney cancer or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for kidney cancer patients, enhancing their chances of effective treatment.
How similar studies have performed: Previous research has shown promising results in understanding immune evasion in various cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Kissick, Haydn — Emory University
- Study coordinator: Kissick, Haydn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.